9 completed, 5 recruiting, 4 terminated, 4 unknown. 25 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 9, Recruiting 5, Terminated 4, Unknown 4, Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 4 | Unknown 3, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Germ Cell Tumor: new trials by email Literature Review of Germ Cell Tumor trials Research Report on Germ Cell Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Zanzalintinib With Etoposide After HDCT in GCT Zanzalintinib, Etoposide Capsule - Germ Cell Tumor | Phase 1 / Phase 2 | Recruiting | Indiana University | 38 | 2025-11-12 | 2025-11-21 |
| A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy Low-dose ASA - Germ Cell Tumor, Testicular Cancer | Phase 2 | Recruiting | Wake Forest University Health Sciences | 35 | 2025-08-28 | 2026-07-24 |
| Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin. Teniposide Injection - GCT, Germ Cell Tumor | Phase 2 | Recruiting | Chengcheng Guo | 40 | 2024-08-13 | 2025-09-23 |
| High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles ) - Germ Cell Tumor | Phase 2 | Recruiting | N.N. Petrov National Medical Research Center of Oncology | 25 | 2024-03-01 | 2025-08-03 |
| CD30 CAR for CD30+ NSGCT ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 2 | 2022-12-09 | 2026-07-07 |
| A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin - Solid Tumors, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Children's National Research Institute | 2022-11-10 | 2025-01-01 | |
| Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor Thalidomide combined with TGA chemotherapy (nab-paclitaxel + gemcitabine+ epirubicin) - Germ Cell Tumor, Yolk Sac Tumor | Phase 2 | Completed | Shandong First Medical University | 20 | 2021-11-11 | 2025-09-18 |
| A Phase II Trial of Cabozantinib With Patients With Refractory GCTs Cabozantinib - Germ Cell Tumor, Seminoma | Phase 2 | Completed | Jennifer King | 50 | 2021-06-10 | 2026-10-16 |
| Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT Etoposide - Germ Cell Tumor, Non-seminomatous Germ Cell Tumor | Phase 2 | Recruiting | Nabil Adra | 64 | 2021-03-03 | 2026-05-08 |
| Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children - Germ Cell Tumor, Yolk Sac Tumor | Phase 2 / Phase 3 | Completed | Shandong First Medical University | 32 | 2020-06-01 | 2025-09-19 |
| Disulfiram and Cisplatin in Refractory TGCTs. Disulfiram - Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute, Slovakia | 12 | 2019-05-14 | 2023-10-04 |
| Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Rolapitant, Palonosetron, Olanzapine - Germ Cell Tumor | Phase 2 | Withdrawn | Costantine Albany | 2018-05-01 | 2019-05-22 | |
| Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Memantine, Placebo, Cognitive Assessment - Glioma of Brain, Craniopharyngioma | Phase 2 | Completed | St. Jude Children's Research Hospital | 41 | 2017-11-07 | 2026-06-23 |
| Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Durvalumab, Tremelimumab - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-05-15 | 2026-09-18 |
| Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Brentuximab Vedotin, Bevacizumab - Germ Cell Tumor | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2017-03-29 | 2020-12-10 |
| Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors Durvalumab, Tremelimumab - Germ Cell Tumor | Phase 2 | Terminated | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 36 | 2017-02-01 | 2021-05-14 |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Genistein, Placebo - Lymphoma, Childhood Lymphoma | Phase 2 | Terminated | University of Virginia | 4 | 2016-08-01 | 2024-05-06 |
| First Line TIP in Poor Prognosis TGCTs. Paclitaxel, Ifosfamide, Cisplatin - Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute, Slovakia | 19 | 2015-04-01 | 2020-08-07 |
| A Pilot RCT of the PRISM Intervention for AYAs With Cancer Promoting Resilience In Stress Management (PRISM) - Cancer, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Seattle Children's Hospital | 92 | 2015-01-30 | 2024-04-09 |
| Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors Bevacizumab, ICE chemotherapy regimen - Germ Cell Tumor | Phase 1 / Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 30 | 2012-04-01 | 2019-02-19 |
Showing 20 of 25. Sign in to see all of them.
Neoplasms, Germ Cell and Embryonal (25) · Nonseminomatous germ cell tumor (5) · Sarcoma (4) · Brain Neoplasms (3) · Endodermal Sinus Tumor (3) · Neoplasms (3) · Sarcoma, Ewing (3) · Seminoma (3) · Wilms Tumor (3) · Germinoma (2) · Hodgkin Disease (2) · Lymphoma (2) · Medulloblastoma (2) · Neuroectodermal Tumors, Primitive (2) · Recurrence (2)
Neoplasms by Histologic Type (25) · Neoplasms (22) · Neoplasms by Site (7) · Urogenital Diseases (6) · Male Urogenital Diseases (5) · Neoplasms, Glandular and Epithelial (5) · Urogenital Neoplasms (5) · Female Urogenital Diseases and Pregnancy Complications (4) · Neoplasms, Connective and Soft Tissue (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Central Nervous System Neoplasms (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Female Urogenital Diseases (3) · Genetic Diseases, Inborn (3)
Cisplatin (4) · Drug Therapy (3) · Bevacizumab (2) · Cyclophosphamide (2) · Etoposide (2) · Ifosfamide (2) · durvalumab (2) · tremelimumab (2) · 130-nm albumin-bound paclitaxel (1) · Aspirin (1) · Brentuximab Vedotin (1) · Carboplatin (1) · Dexamethasone (1) · Disulfiram (1) · Epirubicin (1)
National Cancer Institute, Slovakia (3) · Indiana University (2) · Shandong First Medical University (2) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Assistance Publique - Hôpitaux de Paris (1) · Chengcheng Guo (1) · Children's National Research Institute (1) · Costantine Albany (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Jennifer King (1) · Masonic Cancer Center, University of Minnesota (1) · Memorial Sloan Kettering Cancer Center (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Nabil Adra (1)
United States (14) · China (3) · Slovakia (3) · France (2) · Italy (1) · Russia (1)
Jennifer King, MD (2) · Jingfu Wang, MD (2) · Abby R Rosenberg, MD, MS (1) · AeRang Kim, MD, PhD (1) · Aleksei M Belyaev, MD,DSc,Prof. (1) · Costantine Albany, MD (1) · Edward A Neuwelt (1) · Heather M. Conklin, PhD (1) · Jozef Mardiak, Prof (1) · Landon Brown, MD (1) · Lawrence Einhorn, M.D. (1) · Matthew I Milowsky (1) · Michal Mego, Ass.prof (1) · Michal Mego, Ass.prof. (1)
PMID 24595454, PMID 30243800, PMID 31037789, PMID 31680625, PMID 33960833, PMID 34817581, PMID 36737276
R01NS044687 (1), R21CA218625 (1)